Literature DB >> 11007359

Pharmacodynamics of immunosuppressive drugs.

C Dambrin1, J Klupp, R E Morris.   

Abstract

The inability to measure the effects of immunosuppressive drugs on immune cells in vivo has always severely limited preclinical drug development, the design and interpretation of clinical trials and the optimal clinical use of this drug class in transplantation. Now, new technologies using microliter samples of whole blood and exploiting the specificity, sensitivity and versatility of flow cytometry have been developed. These novel techniques not only are illuminating the 'black box' that has obscured the pharmacodynamic effects of immunosuppressants but also are uncovering new mechanisms of action of these drugs. Pharmacodynamic assays measure biologically relevant events in vivo, since changes in lymphocyte functions in blood collected from immunosuppressed graft recipients faithfully reflect histopathologic events within allograft tissue.

Mesh:

Substances:

Year:  2000        PMID: 11007359     DOI: 10.1016/s0952-7915(00)00138-2

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  8 in total

1.  Pharmacodynamics of T-cell function for monitoring immunosuppression.

Authors:  M J Barten; A Tarnok; J Garbade; H B Bittner; S Dhein; F W Mohr; J F Gummert
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

3.  Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: Responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide.

Authors:  Megan Grobman; Kaitlin A Bishop; Hansjorg Rindt; Laura A Nafe; Carol R Reinero
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

Review 4.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation.

Authors:  Stefano Federico; Rosa Carrano; Domenico Capone; Antonio Gentile; Giuseppe Palmiero; Vincenzo Basile
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation.

Authors:  Nassim Kamar; Petra Glander; Jochen Nolting; Torsten Böhler; Pia Hambach; Lutz Liefeldt; Lionel Rostaing; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 8.237

Review 7.  Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients.

Authors:  Amelia R Cossart; Nicole M Isbel; Carla Scuderi; Scott B Campbell; Christine E Staatz
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

8.  A review on therapeutic drug monitoring of immunosuppressant drugs.

Authors:  Niloufar Mohammadpour; Sepideh Elyasi; Naser Vahdati; Amir Hooshang Mohammadpour; Jamal Shamsara
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.